Ionis Pharmaceuticals (NASDAQ:IONS) Releases Earnings Results, Beats Estimates By $0.29 EPS

Ionis Pharmaceuticals (NASDAQ:IONS) announced its quarterly earnings data on Wednesday. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.29, FiscalAI reports. The firm had revenue of $246.00 million for the quarter, compared to analyst estimates of $195.57 million. Ionis Pharmaceuticals had a negative return on equity of 56.42% and a negative net margin of 30.91%.The company’s revenue was up 86.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.93) EPS.

Here are the key takeaways from Ionis Pharmaceuticals’ conference call:

• TRYNGOLZA launch momentum accelerated in Q1 with growing demand, broadening prescriber mix and initial European rollout with partner Sobi, contributing to $27M in product sales for the quarter.
• Olezarsen (branded TRYNGOLZA) received FDA priority review with a PDUFA of June 30, a new annual WAC of $40,000, and management raised peak U.S. sales expectations to greater than $3 billion based on HCP and payer research.
• Zilganersen’s NDA for Alexander disease was accepted with a PDUFA of September 22, the expanded access program is underway, and the company targets this as its first independent neurology launch.
• Strong Q1 financials: total revenue of $246M (up 87% YoY), cash of ~$1.9B, and raised 2026 revenue guidance to $875M–$900M with product-level guidance for TRYNGOLZA ($100M–$110M) and DAWNZERA ($110M–$120M), plus an improved non‑GAAP operating loss outlook.
• Management expects a significant second-quarter decline in TRYNGOLZA revenue driven by the April 1 price reset to $40,000 before a steady return to growth post-approval for the sHTG indication.

Ionis Pharmaceuticals Stock Up 1.4%

Shares of IONS stock traded up $1.07 during midday trading on Friday, reaching $75.83. 979,301 shares of the stock were exchanged, compared to its average volume of 2,182,419. Ionis Pharmaceuticals has a 1 year low of $31.66 and a 1 year high of $86.74. The firm has a market cap of $12.52 billion, a PE ratio of -36.62 and a beta of 0.40. The company’s 50 day moving average is $75.30 and its two-hundred day moving average is $77.26. The company has a current ratio of 3.83, a quick ratio of 3.81 and a debt-to-equity ratio of 2.76.

Analyst Ratings Changes

IONS has been the subject of several recent research reports. Morgan Stanley boosted their price objective on Ionis Pharmaceuticals from $95.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, April 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $111.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday. Canaccord Genuity Group began coverage on shares of Ionis Pharmaceuticals in a research report on Monday, April 20th. They set a “buy” rating and a $110.00 price target for the company. Stifel Nicolaus raised their price target on shares of Ionis Pharmaceuticals from $73.00 to $77.00 and gave the stock a “hold” rating in a report on Thursday, February 26th. Finally, Wells Fargo & Company boosted their price objective on shares of Ionis Pharmaceuticals from $82.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $99.35.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Kyle Jenne sold 4,902 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $75.17, for a total transaction of $368,483.34. Following the completion of the transaction, the executive vice president owned 23,713 shares of the company’s stock, valued at approximately $1,782,506.21. This trade represents a 17.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Brian Birchler sold 973 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $75.04, for a total transaction of $73,013.92. Following the sale, the executive vice president owned 67,500 shares in the company, valued at approximately $5,065,200. This trade represents a 1.42% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 751,532 shares of company stock valued at $57,680,173 over the last ninety days. Insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IONS. Brown Brothers Harriman & Co. purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth about $27,000. Quarry LP bought a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth approximately $38,000. Johnson Financial Group Inc. bought a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth approximately $44,000. Los Angeles Capital Management LLC purchased a new stake in shares of Ionis Pharmaceuticals in the 4th quarter worth approximately $52,000. Finally, Summit Securities Group LLC purchased a new stake in shares of Ionis Pharmaceuticals in the 4th quarter worth approximately $59,000. 93.86% of the stock is owned by hedge funds and other institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.